Posted by Defense World Staff on Apr 26th, 2025
Geode Capital Management LLC grew its stake in Acelyrin, Inc. (NASDAQ:SLRN – Free Report) by 3.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,709,086 shares of the company’s stock after purchasing an additional 57,472 shares during the period. Geode Capital Management LLC owned approximately 1.70% of Acelyrin worth $5,368,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of SLRN. Wellington Management Group LLP bought a new position in Acelyrin in the 4th quarter worth about $567,000. American Century Companies Inc. boosted its holdings in shares of Acelyrin by 146.0% in the fourth quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock valued at $248,000 after purchasing an additional 46,802 shares during the period. Intech Investment Management LLC grew its stake in Acelyrin by 71.0% in the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after purchasing an additional 11,040 shares in the last quarter. Franklin Resources Inc. increased its holdings in Acelyrin by 36.9% during the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after purchasing an additional 34,642 shares during the period. Finally, Virtu Financial LLC bought a new stake in Acelyrin during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.
Insider Transactions at Acelyrin
In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 13.60% of the company’s stock.
Acelyrin Stock Performance
Shares of SLRN stock opened at $2.17 on Friday. Acelyrin, Inc. has a 12-month low of $1.85 and a 12-month high of $7.25. The business’s fifty day simple moving average is $2.47 and its 200-day simple moving average is $3.37. The company has a market cap of $218.97 million, a PE ratio of -0.88 and a beta of 1.12.
Acelyrin (NASDAQ:SLRN – Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, equities analysts forecast that Acelyrin, Inc. will post -2.53 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have issued reports on SLRN. HC Wainwright dropped their target price on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Citigroup dropped their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.60.
Check Out Our Latest Analysis on SLRN
Acelyrin Profile
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Recommended Stories
- Five stocks we like better than Acelyrin
- What is the S&P/TSX Index?
- Short Sellers Gave Up on These 3 Names Recently
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Boring Stocks Outperforming the Market This Year
- Find and Profitably Trade Stocks at 52-Week Lows
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRN – Free Report).
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.
